Available technologies

Novel apoptosis marker

Reference number: 4277

A novel tracer, 18F-ICMT-11, targeting specific biological processes to improve detection of tumours that are often missed by FDG PET imaging.

Proposed use

18F-ICMT-11 PET imaging can sensitively detect apoptosis, a marker for efficacy in chemotherapy.

Problem addressed

Routine clinical use of PET is based on FDG, a glucose analogue. FDG measures viable cell metabolism. However it lacks specificity and FDG imaging often misses less glycolytic/aggressive tumours. Accordingly, there is a need for tracers targeting specific biological processes and molecular pathways.

Effective anticancer therapy induces tumour cell death through apoptosis. Non-invasive monitoring of apoptosis during therapy may provide predictive outcome information and help tailor treatment. Since a majority of oncology therapies induce apoptosis it could be used as an early and specific signal of therapeutic efficacy.

Technology overview

A team at Imperial College London, led by Eric Aboagye, has developed a novel strategy for the detection of treatment efficacy with 18F-ICMT-11 PET in preclinical models of non-small cell lung carcinoma

The team demonstrated 18F-ICMT-11 is a sensitive marker of chemotherapy-induced cell death in preclinical models of lymphoma, breast and colon cancer. They also showed that apoptotic, but not necrotic response of NSCLC to platinum-based therapy is detectable by 18F-ICMT-11, through sub-nanomolar binding to caspase-3.

18F-ICMT-11 PET has been demostrated to be safe in human patients with a dosimetry profile comparable to other 18F PET tracers.

These results establish 18F-ICMT-11 as a good pharmacodynamic marker of apoptosis and biomarker of efficacy even in the absence of tumour shrinkage.

Benefits

  • Sensitive marker of chemotherapy-induced cell death
  • Safe and well-tolerated in humans
  • Discriminates between apoptosis and necrotic response to platinum-based chemotherapy

Intellectual property information

The technology is protected by a granted patents in the EU and US

WO2010026388A1

Link to published paper(s)

https://pubs.acs.org/doi/10.1021/jm801107u

https://jnm.snmjournals.org/content/54/9/1551.long

https://www.pnas.org/content/106/38/16375

https://clincancerres.aacrjournals.org/content/19/14/3914

https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0091694

https://link.springer.com/article/10.1007/s00259-018-4098-9

Inventor information

Professor Eric Aboagye – Professor of Cancer Pharmacology and Molecular Imaging, Director of the CRUK-EPSRC-MRC-NIHR Comprehensive Cancer Imaging Centre

Download datasheet

contact

Rachel Spruce

Industry Partnerships and Commercialisation Officer, Medicine

r.spruce@imperial.ac.uk

Contact us about this technology

Subscribe for Licensing Opportunities updates
Keep up to date with new technologies and licensing opportunities coming out of Imperial College London